NOTE: ATTENDANCE IS LIMITED TO U.S. LICENSED HEALTHCARE PROFESSIONALS. You must be registered for the ASBMR meeting to attend.
Join us for a timely CME presentation exploring the evolving role of biosimilars in the treatment of osteoporosis in both men and women. This session will review the science behind biosimilars, their clinical applications, and practical considerations for integrating them into patient care to promote bone mass in patients at high risk for fracture. Gain insights into efficacy, safety, and regulatory perspectives, all essential for optimizing treatment strategies in your practice as well as review patient cases where biosimilars may be applied.
Schedule |
|
| * Times are PST | |
| 06:30 AM | Registration and Breakfast Buffet |
| 06:45 AM | Welcome, Disclosures, Supporter Acknowledgement |
| 06:50 AM |
Differences in Biosimilars and Generics: FDA Approval Process
Role of Biosimilars in Increasing Bone Mass in Patients at High Risk for Fracture – Application to Practice |
| 07:30 AM | Closing Comments, Audience Q&A |
| 07:45 AM | Adjourn and Online Evaluation |
Stuart L. Silverman, MD, FACP, FACR
Clinical Professor of Medicine
Cedars-Sinai Medical Center
Los Angeles, CA
E. Michael Lewicki, MD, FACP, FACE, CCD, FASBMR
Director of New Mexico Clinical Research & Osteoporosis Center
Director of Bone Health TeleECHO
University of New Mexico Health Sciences Center
Albuquerque, NM
EXCEL Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
EXCEL Continuing Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Define biosimilars and explain the scientific and regulatory principles guiding their development, evaluation, and approval for the treatment of osteoporosis
- Evaluate the clinical evidence supporting the safety, efficacy, and interchangeability of biosimilar agents in the treatment of osteoporosis
- Apply best practices for integrating biosimilar therapies into clinical management pathways for increasing bone mass in men at high risk for fracture and postmenopausal women with osteoporosis